<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Design of adjuvant trials using trastuzumab</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Design of adjuvant trials using trastuzumab</h1>
<div class="graphic"><div class="figure"><div class="ttl">Design of adjuvant trials using trastuzumab</div><div class="cntnt"><table cellspacing="0"><colgroup span="4" width="25%"></colgroup> <tbody> <tr> <td class="subtitle1">Trial<br/> (number of patients)</td> <td class="subtitle1">Treatment arms</td> <td class="subtitle1">Definition of severe cardiotoxicity</td> <td class="subtitle1">Monitoring frequency</td> </tr> <tr class="divider_bottom"> <td> <p>NSABP B-31<sup>[1]</sup></p> (n = 2030)</td> <td> <p>AC for four cycles, paclitaxel for four cycles, then observation</p> AC for four cycles, followed by paclitaxel for four cycles, with concurrent trastuzumab, continued for one year</td> <td>Grade III/IV HF or cardiac death; or LVEF decrease &gt;15 percentage points*</td> <td>MUGA three weeks, six months, and nine months after end of initial AC, and three months after last trastuzumab dose</td> </tr> <tr class="divider_bottom"> <td> <p>HERA<sup>[2]</sup></p> (n = 5090)</td> <td> <p>Any chemotherapy regimen, then observation</p> <p>Any chemotherapy regimen, then trastuzumab for one year</p> Any chemotherapy regimen, then trastuzumab for two years</td> <td>Severe HF; symptomatic HF; or LVEF decrease &gt;10 percentage points*</td> <td>LVEF (echo or MUGA) at baseline, 3, 6, 12, 18, 24, 30, 36, and 60 months</td> </tr> <tr class="divider_bottom"> <td> <p>BCIRG-006<sup>[3]</sup></p> (n = 3222)</td> <td> <p>AC for four cycles, docetaxel for four cycles, then observation</p> <p>AC for four cycles, followed by docetaxel for four cycles, with concurrent trastuzumab, continued for one year</p> Docetaxel and carboplatin for six cycles, with concurrent trastuzumab, continued for one year</td> <td>Grade III/IV HF; cardiac death; grade 3 to 4 arrhythmias; grade 3 to 4 ischemia/infarction; or LVEF decrease &gt;10 percentage points*</td> <td>After AC, after second dose of docetaxel, at end of chemotherapy, and 3, 12, and 36 months after randomization</td> </tr> <tr class="divider_bottom"> <td> <p>FinHer<sup>[4]</sup></p> (n = 232)<sup>¶</sup></td> <td> <p>Docetaxel (every three weeks) and vinorelbine (weekly) for three cycles, then CEF for three cycles</p> Docetaxel (every three weeks) and vinorelbine (weekly) for three cycles, plus trastuzumab for nine weeks, then CEF for three cycles</td> <td>Myocardial infarction; HF; or LVEF decrease &gt;15 percentage points</td> <td>Echo or MUGA before chemotherapy, after CEF, and 12 and 36 months after chemotherapy</td> </tr> <tr> <td> <p>NCCTG N9831<sup>[5]</sup></p> (n = 3505)</td> <td> <p>AC for four cycles, weekly paclitaxel for 12 weeks, then observation</p> <p>AC for four cycles, weekly paclitaxel for 12 weeks, with concurrent trastuzumab, continued for one year</p> AC for four cycles, weekly placlitaxel for 12 weeks, followed by trastuzumab for one year</td> <td>Grade III/IV HF or cardiac death; or LVEF decrease &gt;15 percentage points*</td> <td>MUGA or echo at entry, after AC, and 6, 9, 18, and 21 months after entry</td> </tr> </tbody></table></div><div class="graphic_footnotes">AC: doxorubicin and cyclophosphamide; HF: heart failure; LVEF: left ventricular heart failure; MUGA: multi-gated acquisition scan; CEF: cyclophosphamide, epirubicin, and fluorouracil.<br/>* Measured from baseline.<br/>¶ Only patients with HER2-positive disease.</div><div class="graphic_reference">References: 

<ol>
<li>Romond EH, et al. N Engl J Med 2005; 353:1673. </li>
<li>Piccart-Gebhart MJ, et al. N Engl J Med 2005; 353:1659. </li>
<li>Slamon D, et al. N Engl J Med 2011; 365:1273. </li>
<li>Joensuu H, et al. N Engl J Med 2006; 354:809. </li>
<li>Perez A, et al. J Clin Oncol 2011; 29:4491.</li></ol>Modified from: Bria E, et al. Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials. Breast Cancer Res Treat 2008; 109:231 and Telli ML, et al. Trastuzumab-related cardiotoxicity: Calling into question the concept of reversibility. J Clin Oncol 2007; 25:3525.</div><div id="graphicVersion">Graphic 70022 Version 9.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
